Biopharmaceutical innovation has traditionally been difficult to capture through market exposures. This article explores how ...
In late June 2026, Vor Biopharma Inc. was added to a broad suite of FTSE Russell indices, including the Russell 2000, 2500, 3000, Microcap, and related growth and value benchmarks. This sweeping ...
Vor Biopharma Inc. (VOR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...
Budget 2026: the Biopharma SHAKTI with an outlay of Rs. 10,000 crores over five years, aimed at strengthening India’s ecosystem for production of biologics and biosimilars. The initiative aligns with ...
6d
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Expands Clinical Development of Neuroprotective Therapy
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum ...
ABVC BioPharma said that the licensing agreement includes the ophthalmology pipeline, including the medical device Vitargus licensed products and clinical trial, registration, manufacturing, supply, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results